Omentin functions to attenuate cardiac hypertrophic response

Area of Science:

• Cardiology
• Endocrinology
• Molecular Biology

Background:

• Cardiac hypertrophy is linked to obesity-related conditions.
• Omentin, an adipose-derived protein, is downregulated in obesity.
• Understanding omentin's role in cardiac function is crucial.

Purpose of the Study:

• To investigate omentin's effect on cardiac hypertrophy in vivo and in vitro.
• To explore the molecular mechanisms underlying omentin's action.
• To assess omentin as a potential therapeutic target for cardiac hypertrophy.

Main Methods:

• Adenoviral vector-mediated omentin delivery in wild-type mice.
• In vitro studies using cultured cardiomyocytes stimulated with phenylephrine.
• AMP-activated protein kinase (AMPK) activation blockade.
• Fat-specific transgenic mice expressing human omentin.

Main Results:

• Omentin administration attenuated cardiac hypertrophy, fibrosis, and ERK phosphorylation.
• Omentin prevented phenylephrine-induced myocyte size increase and ERK phosphorylation.
• Omentin enhanced cardiac AMPK phosphorylation, which was essential for its protective effects.
• Omentin expression in fat tissue reduced cardiac hypertrophy and ERK phosphorylation.

Conclusions:

• Omentin attenuates pathological cardiac hypertrophy via AMPK activation.
• Omentin represents a promising therapeutic target for cardiac hypertrophy treatment.
• Omentin's role in mitigating obesity-related cardiac dysfunction warrants further investigation.